3 research outputs found
Ongoing Phase 1/2 Study Of Incb050465, A Selective Pi3kδ Inhibitor, For The Treatment Of Patients (Pts) With Relapsed/Refractory (R/R) BâCell Malignancies (Citadelâ101)
Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/137307/1/hon2438_139.pd